A Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

ObesityOverweight

Interventions

DRUG

HRS-5817 Injection

HRS-5817 injection administered subcutaneously (SC).

DRUG

HRS-5817 Injection Placebo

HRS-5817 injection placebo administered subcutaneously (SC).

Trial Locations (1)

The Second Hospital of Anhui Medical Uniersity, Hefei

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY